Drug Type Bispecific antibody |
Synonyms PSMAx4-1BB bispecific antibody REGN15505, REGN15505 (PSMAx4-1BB), REGN15505 |
Target |
Action agonists, modulators |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic castration-resistant prostate cancer | Phase 2 | United States | 20 Jul 2026 | |
| Renal Cell Carcinoma | Phase 2 | United States | 20 Jul 2026 |






